In fact, several features driving tumor resistance to this class of drug have been previously described for other cancers, such as CDK genes amplifications and hyperactivation of the PIK3/AKT/mTOR pathway (reviewed in [47]). This evidence concerns the gene PIK3CG and neoplasm.